§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
EP0299698A1 Expired / Lapsed EP ⏱️ 0.0 years remaining

Composition for forming antithrombotic medical appliances

Assignee: Sankyo Co Ltd
•
Filing: 1988-07-11
•
Granted: —
•
Expires: 2008-07-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A composition comprising a polymer having dispersed therethrough a prostacyclin derivative of formula (I): (in which R¹ represents hydrogen or lower alkyl, R² represents a C₃ - C₁₂ alkyl group or a C₃ - C₁₂ alkenyl group; and n is an integer from 1 to 5) and pharmaceutically acceptable salts thereof can be used to make a medical appliance from which the prostaglandin, having antithrombotic properties, will be released gradually and in a controlled way.

Inventors

  • 👤 Kozo Kurihara
  • 👤 Hironobu Saito
  • 👤 Yukie Misho
  • 👤 Takeshi Oshima

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-23 10:30
CPC Classifications
A; A61; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0041

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 69 words
A process for preparing an antithrombotic composition comprising mixing with and distributing through a medically acceptable polymer at least one prostacyclin of formula (I): in which R¹ represents a hydrogen atom or a C₁ - C₆ alkyl group; R² represents a C₃ - C₁₂ alkyl group or a C₃ - C₁₂ alkenyl group; and n is an integer of from 1 to 5; or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim 69 words
A process for preparing an antithrombotic composition comprising mixing with and distributing through a medically acceptable polymer at least one prostacyclin of formula (I): in which R¹ represents a hydrogen atom or a C₁ - C₆ alkyl group; R² represents a C₃ - C₁₂ alkyl group or a C₃ - C₁₂ alkenyl group; and n is an integer of from 1 to 5; or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim 36 words
A process according to Claim 1, in which: R¹ represents a hydrogen atom or a C₁ - C₅ alkyl group; and R² represents a C₄ - C₁₀ alkyl group or a C₅ - C₁₂ alkenyl group.
Claim 4
Dependent Claim 36 words
A process according to Claim 1, in which: R¹ represents a hydrogen atom or a C₁ - C₃ alkyl group; and R² represents a C₄ - C₁₀- alkyl group or a C₅ - C₁₂ alkenyl group.
Claim 5
Dependent Claim 16 words
A process according to any one of Claims 1 to 3, in which n is 3.
Claim 6
Dependent Claim 28 words
A process according to Claim 1, in which said prostacyclin is: 6,9-methylene-11,15-dihydroxyprost-5,13-dienoic acid; 6,9-methylene-11,15-dihydroxy-17-methylprost-5,13-dienoic acid; 6,9-methylene-11,15-dihydroxy-16,16-dimethylprost-5,13-­dienoic acid; 6,9-methylene-11,15-dihydroxy-20-isopropylideneprost-­5,13-dienoic acid; or 6,9-methylene-11,15-dihydroxy-17-methyl-20-isopropyl­ideneprost-5,13-dienoic acid; or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim 137 words
A process according to Claim 1, in which said prostacyclin is: 6,9α-methylene-11α,15α-dihydroxyprost-5( Z ),13( E )-­dienoic acid; 6,9α-methylene-11α,15β-dihydroxyprost-5( Z ),13( E )-­dienoic acid; 6,9α-methylene-11α,15α-dihydroxyprost-5( E ),13( E )-­dienoic acid; 6,9α-methylene-11α,15β-dihydroxyprost-5( E ),13( E )-­dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methylprost-­5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-17-methylprost-­5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methylprost-­5( E ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-17-methylprost-­5( E ),13( E )-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-16,16-dimethyl­prost-5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-16,16-dimethyl­prost-5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-16,16-dimethyl­prost-5( E ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-16,16-dimethyl­prost-5( E ),13( E )-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-20-isopropylidene­prost-5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-20-isopropylidene­prost-5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-20-isopropylidene­prost-5( E ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-20-isopropylidene­prost-5( E ),13( E )-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methyl-20-­isopropylideneprost-5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-17-methyl-20-­isopropylideneprost-5( Z ),13( E )-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methyl-20-­isopropylideneprost-5( E ),13( E )-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-17-methyl-20-­isopropylideneprost-5( E ),13( E )-dienoic acid; or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim 23 words
A composition according to Claim 1, in which said prostacyclin is 6,9α-methylene-11α,15α-dihydroxy-­17-methyl-20-isopropylideneprost-5( E ),13( E )-dienoic acid or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim 56 words
A composition according to any one of the preceding Claims, in which said polymer is cellulose, cellulose acetate, chitin, chitosan, gelatine, collagen, atelocollagen, fibrin, alginic acid or a salt thereof, a polyhydroxyethyl methacrylate, a poly(ether-urethane-­urea), a poly(ether-urethane), a silicone, a poly(amino acid), or a copolymer of any two or more of the monomers forming said polymers.
Claim 10
Dependent Claim 20 words
A process according to Claim 8, in which said polymer is cellulose acetate, a poly(ether-urethane-­urea), a poly(ether-urethane) or a silicone.
Claim 11
Dependent Claim 18 words
A process according to Claim 8, in which said polymer is a poly(ether-urethane-urea), cellulose acetate or a silicone.
Claim 12
Dependent Claim 13 words
A process according to Claim 8, in which said polymer is a silicone.
Claim 13
Dependent Claim 29 words
A process according to any one of the preceding Claims, in which said antithrombotic composition is subsequently formed to produce at least a surface portion of a medical appliance.
Claim 14
Dependent Claim 14 words
A process according to Claim 12, in which said medical appliance is a catheter.
Claim 15
Dependent Claim 22 words
A process according to Claim 12 or Claim 13, in which said antithrombotic composition forms a surface layer only on said appliance.
Claim 16
Dependent Claim 21 words
A process according to Claim 12 or Claim 13, in which said antithrombotic composition forms essentially the whole of said appliance.

References Cited (Backward Citations)

GB2012265A Cited
EP0136916A2 Cited

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag